Common variable immunodeficiency
MONDO:0015517Common variable immunodeficiency (CVID) comprises a heterogeneous group of diseases characterized by a significant hypogammaglobulinemia of unknown cause, failure to produce specific antibodies after immunizations and susceptibility to bacterial infections, predominantly caused by encapsulated bacteria.
Also known as: Common Variable Immune Deficiency, idiopathic immunoglobulin deficiency, primary antibody deficiency, primary hypogammaglobulinemia, secondary hypogammaglobulinemia, Immunoglobulin deficiency, late-onset, acquired agammaglobulinemia, acquired hypogammaglobulinemia
68 clinical trials for this condition and its sub-types, 29 tagged with Common variable immunodeficiency itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Common variable immunodeficiency
-
Immune deficiency, familial variable 0 trials
-
Immunodeficiency, common variable, 1 0 trials
-
1 sub-type
-
Immunodeficiency, common variable, 2 0 trials
-
Immunodeficiency, common variable, 3 0 trials
-
Immunodeficiency, common variable, 4 0 trials
-
Immunodeficiency, common variable, 5 0 trials
-
Immunodeficiency, common variable, 6 0 trials
-
Immunodeficiency, common variable, 7 0 trials
-
Could a common supplement help rare lung disease?
Disease control OngoingThis phase 2 trial tests whether the supplement fisetin can improve lung disease in people with common variable immunodeficiency (CVID). Twenty participants will receive either fisetin or a placebo on four days over a month. The study measures changes in immune cells and lung fun…
Phase 2 • Sponsor: Avni Joshi • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Stem cell transplant offers new hope for kids with rare immune diseases
Disease control OngoingThis study tests a donor stem cell transplant for people with severe immune system problems, like SCID and Wiskott-Aldrich syndrome. The goal is to help the body make healthy blood cells and fight infections. Participants receive donated stem cells to rebuild their immune system.…
Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a new immune system fix T-Cell diseases? trial tests donor transplants
Disease control OngoingThis study tests whether a stem cell transplant from a healthy donor can safely treat people with severe T-cell problems. Participants receive chemotherapy and antibody therapy before the transplant, followed by donor stem cells. The goal is to see if the new immune system can co…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Milder stem cell transplant shows promise for kids with immune disorders
Disease control OngoingThis study tests a stem cell transplant using a milder chemotherapy-like regimen to treat children and young adults (up to age 28) with various immune system disorders. The goal is to help the donor stem cells settle in the body with fewer side effects. The study involves 20 part…
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Double transplant breakthrough offers hope for rare immune disorder patients
Disease control By invitation onlyThis study tests a new approach for people aged 5 to 45 with primary immune deficiencies and end-stage lung disease. Participants receive a double lung transplant followed by a stem cell transplant from the same donor. The goal is to see if this combined procedure is safe and can…
Phase 1/2 • Sponsor: Paul Szabolcs • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Scientists collect skin cells to pave way for future immune disease cures
Knowledge-focused By invitation onlyThis study collects small skin samples from people with primary immunodeficiency or immune regulation disorders, as well as from healthy volunteers. Researchers will use these cells to create cell lines for laboratory research. The goal is to better understand immune diseases and…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC